Study:
A Phase I/II Study Of Neoadjuvant Chemotherapy, Angiogenesis Inhibitor SU5416 (NSC # 696819; A TK Inhibitor Anti-Angionesises Compound), And Radiation Therapy In The Management Of High Risk, High-Grade, Soft Tissue Sarcomas Of The Extremities And Body Wall
Rationale:
Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Drugs such as SU5416 may stop the growth of cancer by stopping
blood flow to the tumor. Radiation therapy uses high-energy x-rays to damage tumor cells.
Giving chemotherapy, SU5416, and radiation therapy before and after surgery may kill more
tumor cells.
Purpose:
Phase I/II trial to study the effectiveness of chemotherapy, SU5416, radiation
therapy, and surgery in treating patients who have soft tissue sarcoma.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Sarcoma |
Biological: filgrastim
Drug: dacarbazine
Drug: doxorubicin hydrochloride
Drug: ifosfamide
Drug: semaxanib
Procedure: conventional surgery
Radiation: radiation therapy |
Phase 1/Phase 2 |
Verified by
Radiation Therapy Oncology Group
December, 2010
Sponsored by: Radiation Therapy Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00023738
Study Type: Interventional
Study Design: Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Burton L. Eisenberg, MD., Study Chair